Calls
1
u/investak
Reddit r/wallstreetbets
Win Rate
100.0%
return
+72.0%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 14
$39.99
+72.0%
Author argues Liquidia's Yutrepia is eating into JNJ's Uptravi and UTHR's Tyvaso, which together represent a ~$3.62B TAM. Yutrepia is claimed to be superior in side effects and usability, and with 2,200 patients generating $148M in H2 2025 (ARPP ~$140k), the author projects Q1 2026 revenue of at least $110M+ and ~6,750 patients (30% market share) by mid-2027, implying $900M+ annual revenue. At a $3B market cap, the author calls the stock a steal. No specific risk is stated.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/investak has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: LQDA.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
